Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
39 results
D1.19 - Etoricoxib-Induced Fixed Drug Eruption: A Case Series and Assessment of Tolerance to Alternative NSAIDs
D1.27 - Delayed Hypersensitivity Reactions to Iodinated Contrast Media: Diagnostic Outcomes and Alternative Selection
D1.17 - Service Evaluation of patients with Suspected Allergic Reactions presenting to the Emergency Department of a tertiary Irish teaching hospital
D1.18 - Not Just for Kids: A Rare Case of Adult-Onset IgE-Mediated Cow’s Milk Allergy Masquerading as Drug Hypersensitivity
D1.20 - Challenges in Safe Alternative Selection in a Case of Amoxicillin-Induced Anaphylaxis
D1.21 - Three cases of Food induced Anaphylaxis - Role of Cofactors
D1.25 - Cannabis-Fruit-Veggie Syndrome: From Respiratory Symptoms to Life-Threatening Anaphylaxis
D1.26 - Egg Allergy Persistence Beyond 8 Years of Age
D1.28 - Clinical Follow-up in Radiocontrast Media–Induced Hypersensitivity Reactions: Beyond the Reaction
D1.29 - When Anaphylaxis Is Not Anaphylaxis: A Rare Differential Diagnosis in Perioperative Shock
D1.30 - Allergy Care in Adult Cystic Fibrosis Patients with Drug Hypersensitivity: A Service Evaluation at St Bartholomew’s Hospital
D1.31 - Identification of Process-Modified Allergens in Tiger Nut Milk (Horchata) as the Cause of IgE-Mediated Anaphylaxis: Molecular Evidence of Aldolase and α/β-Hydrolase Proteins
D1.105 - Real-Life Evidence of Type 2 Immunomodulation with Benralizumab: From Steroid-Dependent to Controlled Asthma
D1.106 - Dupilumab-Induced Systemic Eosinophilic Immune Activation Mimicking an EGPA-Like Prodrome: A Case Report
D1.108 - Optimization of phenotyping in severe T2-bronchial asthma
D1.109 - Biologics selection algorithm for severe T2-bronchial asthma targeted therapy
D1.110 - Long Term Mepolizumab in Type-2 CRSwNP: Marked Polyp Reduction, Symptom Relief, and Airway Benefits in Real World Comorbid Patients
D1.111 - Tezepelumab reduces in patients with severe allergic asthma and rhinoconjunctivitis not only bronchial but also nasal and conjunctival symptoms – results from an exposure chamber study
D1.112 - ILC2 Expansion as a Biomarker of Suboptimal Response to Dupilumab in Severe Asthma: Findings from the PRISM Study
D1.113 - Effect of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a real-world retrospective observational study
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download